The lymphocyte depletion classical Hodgkin lymphoma (LDCHL) is the less common subtype of cHL. In LDCHL, Hodgkin and Reed-Sternberg (HRS) cells grow within a background depleted in reactive lymphocytes. LDCHL subtype accounts for only a small fraction of all HL cases in Western countries. It also occurs in people with HIV/AIDS. The HRS cells show the same immunophenotype as in the other subtypes of cHL.
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Identity

Other names
Lymphocyte depletion Hodgkin Lymphoma Lymphocyte-depleted classical Hodgkin lymphoma Lymphocyte depletion Hodgkin disease.
Clinics and pathology
Disease
Hodgkin Lymphoma (HL) includes classical Hodgkin lymphoma (CHL) which accounts for 95% of all cases . Lymphocyte depletion classical Hodgkin lymphoma (LDCHL) is the less common subtype of cHL (Benharroch et al., 2008) . LDCHL is a subtype of cHL rich in Hodgkin and Reed-Sternberg (HRS) cells. These cells reside within a background depleted in non-neoplastic lymphocytes. In the past few decades, a fraction of these cases have been reclassified into different nonHodgkin lymphoma entities (Benharroch et al., 2008) .
Phenotype/cell stem origin
LDCHL involves a clonal expansion of germinal center B-cell derived lymphocytes which mimic those observed in the other subtypes of cHL.
Epidemiology
LDCHL accounts for only a small fraction, less than 1%, of all HL cases in Western countries. There is a male predominance. The median age ranges from 30 to 40 years. LDCHL is often seen in people infected with HIV and more often in developing countries (IARC, 2012) . People with HIV/AIDS are at increased risk of HL in the highly active antiretroviral therapy era. In HIV-infected people cHL is presently the most common non-AIDS defining cancer (Carbone et al., 2014) .
Clinics
Patients affected by LDCHL present with an advanced stage (III-IV stage) and with B symptoms more often than those affected by the other subtypes. LDCHL usually involves retroperitoneal lymphnodes and extranodal sites including abdominal organs and bone-marrow (Younes et al., 2014) . It has been recognized that EBV has the capability to modulate the tumour microenvironment (Dolcetti, 2015; Dolcetti et al., 2016) .
Treatment
The combination of cART with better supportive therapy has made standard ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), used for LDCHL occurring in the general population, feasible in patients with HIV-associated Hodgkin lymphoma (Carbone et al., 2014) .
Prognosis
Most patients affected by LDCHL have a worse prognosis than do patients affected by other cHL subtypes (Younes et al., 2012) . Poor prognosis have been observed in patients affected by HIV-associated LDCHL. The outcome of HIV-associated cHL has dramatically improved since the introduction of cART with intensive chemotherapy regimens (Carbone et al., 2014) .
Genetics
Due to the small number of LDCHL cases analysed for genetics/cytogenetics characteristics and to the reclassification of cases into different lymphoma categories, the previously described genetics and cytogenetics findings are not unquestionably acknowledged.
